Merck announces positive BRUNELLO trial results for remigromig in diabetic macular edema
FROM THE WIRE · FINANCE.YAHOO.COM
Remigromig demonstrated non-inferiority in mean change from baseline in best corrected visual acuity versus ranibizumab at one year in patients with diabetic macular edema (DME) Remigromig is the first biologic with a novel mechanism of action to demonstrate non-inferior visual…
Read at the source ↗MARKET IMPACTHIGH✦ News Impact agent estimateTone: expected bullishRemigromig demonstrated non-inferiority versus anti-VEGF therapy, representing a potential first-in-class with novel mechanism for a disease with significant…AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Remigromig achieved non-inferiority in best corrected visual acuity change versus ranibizumab at one year in diabetic macular edema…
- 02It is the first biologic with novel mechanism of action to demonstrate non-inferior visual acuity versus anti-VEGF therapy in a pivotal DME…
- 03Up to 40% of DME patients have persistent disease after six months, highlighting the need for new therapeutic approaches.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets